Retrospective hunt for hope in tough brain cancer cases

This study looks back at medical records to see how well the drug ibrutinib worked for adults with a rare and aggressive brain lymphoma (PCNSL) that has come back or did not respond to standard treatment. Researchers will analyze data from 36 patients who received ibrutinib, either alone or combined with another chemotherapy regimen, to see how many responded to treatment and how long they lived. The goal is to gather real-world evidence to help guide treatment for this difficult-to-treat condition.